YOKNEAM, Israel, May 18, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (Nasdaq:LMNS), the world's largest energy-based medical device company for surgical, ophthalmology, and aesthetic applications announced today that its novel laser urology platform, the Lumenis Pulse 120H, has received the Red Dot Award: Product Design 2015.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=33004
4,928 entries from 56 countries were included in the competition and reviewed by a 38-member jury to identify the products with the highest level of quality and innovation.
Lumenis Pulse 120H represents a new standard for power, speed, safety and cost-efficiency in holmium laser surgery and provides superior clinical outcomes for patients living with highly prevalent urological conditions like benign prostatic hyperplasia (BPH) and kidney stones. It offers a comprehensive solution for enhanced Vaporization, Enucleation, Flexible Ureteroscopy and Percutaneous Nephrolithotomy (PCNL) procedures.
Currently featured at the American Urological Association 2015 Annual Meeting (booth #1317), where physicians are being trained on the technology, the Lumenis Pulse 120H represents the latest in a series of innovations from Lumenis for the dynamic and growing market for urological procedures worldwide.
For the system design, Lumenis chose Taga, an industrial product design and development firm specializing in medical devices. The designers and engineers at Taga have worked closely with Lumenis, taking into account all product aspects through the full life cycle, giving attention to every detail.
To learn more about the Lumenis Pulse 120H, visit www.lumenis.com/Solutions/Surgical/lumenis-pulse-120H.
About the Red Dot Award
In order to appraise the diversity in the field of design in a professional manner, the Red Dot Design Award breaks down into the three disciplines of Red Dot Award: Product Design, Red Dot Award: Communication Design and Red Dot Award: Design Concept.
The Red Dot Award was created by Design Zentrum Nordrhein Westfalen and with around 17,000 entries each year is one of the best-respected design competitions in the world. In 2015, it is celebrating its 60th anniversary: It was in 1955 that a jury convened for the first time to assess the best designs of the day. The sought-after award, the "Red Dot", is the revered international seal of outstanding design quality.
About Lumenis
Lumenis (Nasdaq:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. For more information visit: www.lumenis.com
Forward-Looking Statements
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
